( SAN FRANCISCO--(BUSINESS WIRE)--May 21...)Nektar Threraputics Announces Phase 2a Clinical Results Regarding,the use of NKTR-061 (Inhaled Amikacin) to Treat Gram-Negative,Hospital-Acquired Pneumonia Presented at the Annual American,Thoracic Society International Conference,Health

SAN FRANCISCO--(BUSINESS WIRE)--May 21, 2007 - Medical professionals seeking to treat the serious and growing problem of hospital-acquired gram-negative pneumonia may have a new weapon: NKTR-061 (inhaled-amikacin), which is a product candidate being developed by Nektar Therapeutics (Nasdaq:NKTR).

Results of a Phase 2a clinical trial evaluating the use of NKTR-061 (Inhaled Amikacin) to treat mechanically ventilated patients with hospital-acquired gram-negative pneumonia were presented today during a poster session from 11:15 a.m. - 2:00 p.m. Eastern Time (8:15 a.m. - 11:00 a.m. Pacific Time) at the annual American Thoracic Society (ATS) International Conference at the San Francisco Marriott Hotel. Electronic copies of the posters presented are available on the Investor Relations section of www.nektar.com.

"The data in this study are very encouraging because they indicate that the adjunctive use of aerosol antibiotics with systemic therapy might be an effective new approach for treating patients infected by hospital-acquired, gram negative pneumonia, many of whom were infected by resistant gram negative pathogens," said Michael S. Niederman, M.D., chairman of the Department of Medicine at the Winthrop-University Hospital and Professor of Medicine at the State University of New York at Stony Brook in Minneola, New York, a lead investigator who presented the data today. "The key to effectively treating this difficult clinical condition is delivering high concentrations of antibiotics to the site of infection, particularly the pneumonic portions of the lung, and thereby eradicating the pathogens. The findings in the study raise the real possibility that the efficacious delivery of aerosolized antibiotics with the system used in this study can lead clinicians to use less systemic antibiotics, while still achieving clinical success. This in turn may make it possible to avoid further development of antibiotic resistance, which is a serious problem in this patient
'"/>

Page: 1 2 3 4 5 6 7 8 9 10 11
Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product